These data, and recent advances in vaccine design, suggest that it may be possible to design a vaccine in which vaccine-induced HIV-specific CD4+ T cells are less susceptible to infection than those usually produced during HIV infection. This evidence concerns the gene CD4 and HIV infectious disease.